tesamorelin dosage hiv lipodystrophy: Frequently asked questions

Unreconstituted lyophilised tesamorelin powder tolerates room temperature (20-25°C) for up to 7 days without significant potency loss, but reconstituted solution degrades rapidly above 8°C. If a mixed vial was left at room temperature for 8-12 hours, the peptide structure may have partially denatured. There's no home test to verify potency, so the safest approach is to discard the vial and reconstitute a fresh one. Temperature excursions compromise molecular stability in ways that neither appearance nor injection site reactions reliably indicate.

No. Take the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your regular schedule. If more than 12 hours have elapsed, skip the missed dose entirely and continue with your next scheduled injection. Doubling the dose (4mg) produces no additional GH release because GHRH receptors are already saturated at 2mg. The extra peptide circulates unbound and increases side effect probability (joint pain, fluid retention) without therapeutic benefit. Missing occasional doses delays VAT reduction progress proportionally but does not negate prior weeks' effects.

Arthralgia (joint pain) occurs in 18-22% of tesamorelin patients and typically peaks during weeks 4-8 before resolving spontaneously as the body adapts to elevated GH levels. Reducing the dose to 1.5mg or 1mg does decrease joint pain incidence but also reduces VAT reduction proportionally. Most patients who tolerate the discomfort through week 12 report complete resolution without dose adjustment. If pain persists beyond 12 weeks or limits daily function, consult your prescriber before modifying the dose. Switching injection sites or adjusting timing relative to meals resolves symptoms in 40% of cases without compromising efficacy.

VAT reduction follows a logarithmic curve, not a linear one. Most patients experience the steepest decline in the first 12 weeks (8–12% reduction) with slower progress from weeks 12–26 (an additional 3–6% reduction). This plateau pattern is physiological. Visceral adipocytes adapt to sustained lipolytic signalling by downregulating GHRH receptor density. Increasing the dose above 2mg doesn't overcome this adaptation and increases adverse event risk. If VAT hasn't declined by at least 5% by week 12, review reconstitution technique and injection timing. Preparation errors are the most common cause of non-response.

Administer the missed dose as soon as you remember if it's still nighttime (before 2am). If you wake up the next morning and realise you missed the previous night's dose, skip it entirely and resume your regular schedule that evening. Do not double-dose to compensate. Missing a single dose creates a 24-hour gap in GH stimulation but doesn't reverse VAT reduction progress. Missing three or more doses per week, however, significantly reduces cumulative efficacy: adherence below 80% correlates with VAT reductions of only 6–9% at 26 weeks.

Injection site erythema, swelling, or pruritus occurs in 35–40% of patients during the first 8–12 weeks and typically resolves with continued use as local immune tolerance develops. Rotate injection sites across the abdomen in a systematic pattern (alternating quadrants nightly) to prevent cumulative irritation in any single area. If reactions persist beyond 12 weeks or worsen over time, switch to a different reconstitution technique. Some patients react to preservatives in bacteriostatic water and benefit from reconstituting with preservative-free sterile water instead, though this reduces shelf life to three hours post-mixing.